November 15, 2024, Burlington, MA – PharmaEssentia Corporation (TWSE: 6446), a global commercial biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that it will participate in the following investor conferences.

• Jefferies London Healthcare Conference

London, United Kingdom

November 20, 2024 – Presentation at 10:30 a.m. GMT

• 2024 Citi’s Global Healthcare Conference

Miami, FL

December 3, 2024

Any live sessions and replays of the webcasts will be available on

https://wsw.com/webcast/jeff315/6466/1539384 for at least 30 days.

About PharmaEssentia

PharmaEssentia (TPEx: 6446), headquartered in Taipei, Taiwan, is a commercial-stage, global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology, oncology, and immunology with one approved product and a diversified pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production

facility in Taichung, Taiwan.

For more information about PharmaEssentia USA, visit the website, LinkedIn or X (formerly Twitter).

Investor and Media Contact

Muriel Huang, muriel_huang@pharmaessentia.com

# # #

© 2024 PharmaEssentia Corporation. All rights reserved.